Intralesional therapies, such as T-VEC, BCG, PV-10, and IL2 can promote neoantigen exposure (through viral antigens, HMB-PP, HMGB1 proteins, and melan-A, respectively), possibly turning weakly immunogenic tumors into strongly immunogenic tumors and promoting anti-tumor immunity. The gene discussed is HMGB1; the disease is neoplasm.